Cargando…

Erratum to: Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor

Detalles Bibliográficos
Autores principales:	Bounameaux, Henri, Camm, A. John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2014
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643581/ http://dx.doi.org/10.1007/s40265-014-0280-y

Ejemplares similares

Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
por: Bounameaux, Henri, et al.
Publicado: (2014)

Determination of Anti-Xa Inhibitor Plasma Concentrations Using a Universal Edoxaban Calibrator
por: Burger, Annika, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor
por: Mendell, Jeanne, et al.
Publicado: (2013)

Edoxaban, a direct oral factor Xa inhibitor, ameliorates coagulation, microvascular thrombus formation, and acute liver injury in a lipopolysaccharide-induced coagulopathy model in rats
por: Morishima, Yoshiyuki, et al.
Publicado: (2021)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
por: Upreti, Vijay V, et al.
Publicado: (2013)

Edoxaban, a Factor Xa-Specific Direct Oral Anticoagulant, Significantly Suppresses Tumor Growth in Colorectal Cancer Colon26-Inoculated BALB/c Mice
por: Hiramoto, Keiichi, et al.
Publicado: (2023)

Factor Xa inhibitor, edoxaban ameliorates renal injury after subtotal nephrectomy by reducing epithelial‐mesenchymal transition and inflammatory response
por: Fang, Lixin, et al.
Publicado: (2022)

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
por: Verhoef, Daniël, et al.
Publicado: (2017)

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Erratum: Update of Sepsis: Recent Evidences about Early Goal Directed Therapy
por: Cho, Woo Hyun
Publicado: (2015)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
por: Persson, Pontus B
Publicado: (2015)

Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
por: Wong, Pancras C., et al.
Publicado: (2011)

Rivaroxaban, a Direct Oral Factor Xa Inhibitor, Attenuates Atherosclerosis by Alleviating Factor Xa–PAR2-Mediated Autophagy Suppression
por: Ito, Yusuke, et al.
Publicado: (2021)

The new factor Xa inhibitor: Apixaban
por: Bhanwra, Sangeeta, et al.
Publicado: (2014)

Erratum to: Neurocritical care update
por: Kuroda, Yasuhiro
Publicado: (2016)

Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa
por: Bourdin, Matthieu, et al.
Publicado: (2021)

Impact of Renal Function on Anti-factor Xa Activity Concentrations with Edoxaban Use in Patients with Non-valvular Atrial Fibrillation
por: Ono, Ryohei, et al.
Publicado: (2022)

Direct oral Xa inhibitors for the treatment of venous thromboembolism after bariatric surgery
por: Kushnir, Margarita, et al.
Publicado: (2022)

Erratum to: Heart disease in the Netherlands: a quantitative update
por: Leening, M. J. G., et al.
Publicado: (2014)

Erratum to “An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity”
por: Chen, Chun-Bing, et al.
Publicado: (2019)

Erratum to: ISCEV Standard for clinical electro-oculography (2017 update)
por: Constable, Paul A., et al.
Publicado: (2017)

Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections
por: Al-Horani, Rami A.
Publicado: (2020)

Erratum to “Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac”
por: Walker, Chris
Publicado: (2019)

Rivaroxaban – an oral, direct Factor Xa inhibitor – lessons from a broad clinical study programme
por: Haas, Sylvia
Publicado: (2009)

Erratum to: An Update on Implants for Minimally Invasive Glaucoma Surgery (MIGS)
por: Ansari, Ejaz
Publicado: (2017)

Erratum: Pathophysiology and Management of Alcoholic Liver Disease: Update 2016
por: Stickel, Felix, et al.
Publicado: (2017)

A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation
por: Willekens, Guido, et al.
Publicado: (2021)

The Development of New Factor Xa Inhibitors Based on Amide Synthesis
por: Tarasov, Dmitry N., et al.
Publicado: (2018)

Erratum: IAPCON 2020 Abstracts-Oral Presentations
Publicado: (2020)

ERRATUM: Corrected Figure Legend: Stroke Genetics: A Review and Update
por: Lindgren, Arne
Publicado: (2015)

Erratum: Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates
Publicado: (2017)

Erratum to “Beyond the Definitions of the Phenotypic Complications of Sickle Cell Disease: An Update on Management”
por: Ballas, Samir K., et al.
Publicado: (2013)

Application of Molecular Modeling to Development of New Factor Xa Inhibitors
por: Sulimov, Vladimir B., et al.
Publicado: (2015)

Erratum: Correction of Acknowledgements Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2019)

Erratum: New Developments at EHP
Publicado: (2015)

Effect of dexamethasone on direct Xa-inhibitor oral anticoagulant plasma levels in patients with COVID-19
por: Bosch, Floris T.M., et al.
Publicado: (2021)

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
por: Frost, Charles, et al.
Publicado: (2013)

Erratum to: New Directions for Rabbit Antithymocyte Globulin (Thymoglobulin(®)) in Solid Organ Transplants, Stem Cell Transplants and Autoimmunity
por: Mohty, Mohamad, et al.
Publicado: (2014)

Erratum to: An updated review of case–control studies of lung cancer and indoor radon-Is indoor radon the risk factor for lung cancer?
por: Sheen, Seungsoo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_a02nir4jdlqb1n208u9068rhki